Form 4 Tracker
Joseph P Lyssikatos

CHIEF SCIENTIFIC OFFICER · 3 filings · Latest: Feb 12, 2026

Enliven Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
ELVN
Lyssikatos Joseph PApr 30, 2026
Proposed Sale
$42.4025,000$1.1M
ELVN
Lyssikatos Joseph PMar 31, 2026
Proposed Sale
$36.5925,000$914.8K
ELVN
Lyssikatos Joseph PFeb 18, 2026
Proposed Sale
$26.1375,000$2.0M
ELVN
Joseph P LyssikatosCHIEF SCIENTIFIC OFFICERFeb 6, 2026
Sale
$29.045,000$145.2K740,188
ELVN
Joseph P LyssikatosCHIEF SCIENTIFIC OFFICERJan 20, 2026
Sale
$26.7520,000$535.1K745,188
ELVN
Lyssikatos Joseph PJan 9, 2026
Proposed Sale
$23.2575,000$1.7M
ELVN
Lyssikatos Joseph PJan 8, 2026
Proposed Sale
$15.4782,500$1.3M
ELVN
Lyssikatos Joseph PDec 19, 2025
Proposed Sale
$16.685,000$83.4K
ELVN
Lyssikatos Joseph PNov 19, 2025
Proposed Sale
$22.5912,500$282.4K
ELVN
Lyssikatos Joseph POct 20, 2025
Proposed Sale
$21.4112,500$267.6K
ELVN
Lyssikatos Joseph PSep 19, 2025
Proposed Sale
$19.9312,500$249.1K
ELVN
Lyssikatos Joseph PAug 19, 2025
Proposed Sale
$19.7512,500$246.9K
ELVN
Lyssikatos Joseph PJul 21, 2025
Proposed Sale
$22.6612,500$283.3K
ELVN
Lyssikatos Joseph PJun 20, 2025
Proposed Sale
$21.5712,500$269.6K
ELVN
Lyssikatos Joseph PJun 3, 2025
Proposed Sale
$19.147,500$143.6K
ELVN
Lyssikatos Joseph PMay 19, 2025
Proposed Sale
$16.865,000$84.3K
ELVN
Lyssikatos Joseph PMay 1, 2025
Proposed Sale
$18.947,500$142.1K
ELVN
Lyssikatos Joseph PApr 21, 2025
Proposed Sale
$16.535,000$82.7K
ELVN
Lyssikatos Joseph PMar 19, 2025
Proposed Sale
$20.2812,500$253.5K
ELVN
Lyssikatos Joseph POct 18, 2024
Proposed Sale
$28.0265,000$1.8M

Page 1 of 2

Next →